<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.00499.017</object-id><label>Table 1.</label><caption><p>Enrichment of F876 mutant expressing cells after enzalutamide or ARN-509 exposure</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.00499.017">http://dx.doi.org/10.7554/eLife.00499.017</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><td/><td>F876 mutation<xref ref-type="table-fn" rid="tblfn1">*</xref></td><td>Treatment</td></tr></thead><tbody><tr><td rowspan="3">CWR22PC (in vitro)</td><td>52% of all reads</td><td>Enzalutamide</td></tr><tr><td>1.3% of all reads</td><td>ARN-509</td></tr><tr><td>not detected</td><td>Vehicle</td></tr><tr><td rowspan="3">LNCaP/AR (in vivo)</td><td>3/8 tumors<xref ref-type="table-fn" rid="tblfn1">*</xref></td><td>Enzalutamide</td></tr><tr><td>3/14 tumors</td><td>ARN-509</td></tr><tr><td>0/5 tumors</td><td>Vehicle</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>*</label><p>One tumor F876I, all others F876L</p></fn></table-wrap-foot></table-wrap>